BTK Inhibition Strategies in B-Cell Malignancies: Expert Perspectives to Guide Clinical Decisions

Register now to hear expert insights on the optimal treatment of B-cell malignancies with BTK inhibitors in this interactive, case-based 1-hour live meeting. After the meeting, download the associated slideset for use in your clinic.

Agenda

Overview: BTK in Oncogenic Signaling in B-Cell Malignancies

Maximizing Clinical Outcomes With BTK Inhibitors and BTK Inhibitor–Based Combinations in B-Cell Malignancies

Case Discussions: Practical Application of BTK inhibitor Therapy in B-Cell Malignancies
Includes case examples with interactive questions to highlight optimal use of BTK inhibitors in clinical practice

Future Directions

Final Thoughts and Question and Answer Session

Events

Date / Time
Event Details

Faculty

Co-Chair
Jeremy Abramson, MD

Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

Co-Chair
Christopher R. Flowers, MD, MS

Department Chair,
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Goal Statement
The goal of this activity is to improve participants’ competence in using BTK inhibitors (and emerging BTK inhibitor–based combinations) to improve treatment outcomes for patients with MCL, MZL, CLL/SLL, and WM.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with MCL, MZL, CLL/SLL, and WM.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan optimal, individualized therapeutic strategies for patients with MCL, MZL, CLL/SLL, and WM considering recent practice changing clinical trial results
  • Consider existing and emerging clinical research data evaluating currently available and emerging BTK inhibitors (and BTK inhibitor–based combinations) in the formulation of therapeutic recommendations for patients with MCL, MZL, CLL/SLL, and WM
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support quality of life and continuation of treatment
  • Explain to patients the importance of and provide strategies for optimal adherence to prescribed BTK inhibitors
  • Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK inhibitor–based combinations) to aid clinical trial enrollment

Accreditation

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, International Myeloma Foundation and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.